First COVID-19 Antibody Drug Authorized for Emergency Use

November 13, 2020

Earlier this week, the Food and Drug Administration (FDA) granted emergency use authorization of the first COVID-19 antibody drug, bamlanivimab, for mild-to-moderate COVID-19 in adult and pediatric patients. For high risk COVID-19 patients, this drug reduces the need for hospitalization or emergency room care. 

Bamlanivimab can be used for:

  • Anyone over the age of 65 or someone with certain chronic medical conditions who has been recently diagnosed with mild-to-moderate COVID-19 

  • Patients age 12 and older who weigh at least 88 pounds and who are at high risk for progressing to severe COVID-19 and/or hospitalization

  • This medication is not authorized for COVID-19 patients who are hospitalized or for those who require oxygen.

The manufacturer of bamlanivimab is Eli Lilly and Company.

If you have questions, please contact the ISMS Health Policy Research and Advocacy team by email.

Share this article:

Cookie Consent

Cookies are required for some functionality on our site. View our privacy policy for more information.